Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...

BioAge Labs aims to help those medications work better with a lead drug candidate envisioned as a part of new GLP-1 combination therapies. With a key clinical trial already underway, BioAge has ...